Hepatorenal syndrome

Lancet

Volumn 362, Issue 9398, 2003, Pages 1819-1827

  Ginès, Pere ^a,b   Guevara, Mónica ^a   Arroyo, Vicente ^a   Rodés, Juan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; BICARBONATE; MIDODRINE; NORADRENALIN; ORNIPRESSIN; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; TERLIPRESSIN;

CLINICAL EXAMINATION; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC TEST; DRUG EFFICACY; FLUID INTAKE; HEPATORENAL SYNDROME; HUMAN; HYPERKALEMIA; INCIDENCE; ISCHEMIA; KIDNEY TRANSPLANTATION; LABORATORY TEST; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATHOGENESIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 0344256499     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14903-3     Document Type: Conference Paper

References (93)

1. Papper S. Hepatorenal syndrome. Epstein M. The kidney in liver disease. 1st edn:1978;91-112 Elsevier Biomedical, New York.
2. Ginès P., Rodés J. Clinical disorders of renal function in cirrhosis with ascites. Arroyo V., Ginès P., Rodés J., Schrier R.W. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment. 1999;36-62 Blackwell Science, Malden.
3. Hecker R., Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet. 2:1956;1121-1125.
4. Epstein M., Berck, Hollemberg N.K., et al. Renal failure in the patient with cirrhosis: the role of active vasoconstriction. Am J Med. 49:1970;175-185.
5. Arroyo V. Milestones in liver disease. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure [Lancet 1956; 2: 1221-25]. J Hepatol 2002; 36: 315-20.
6. Arroyo V., Ginès P., Gerbes A., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 23:1996;164-176.
7. Wilkinson S.P., Blendis L.M., Williams R. Frequency and type of renal and electrolyte disorders in fulminant hepatic failure. BMJ. 1:1974;186-189.
8. Ellis A.J., O'Grady J.G. Clinical disorders of renal function in acute liver failure. Arroyo V., Ginès P., Rodés J., Schrier R.W. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment. 1999;36-62 Blackwell Science, Malden.
9. Akriviadis E., Botla R., Briggs W., Han S., Reynolds T., Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 119:2000;1637-1648.
10. Schroeder E.T., Shear L., Sancetta S.M., Gabuzda G.J. Renal failure in patients with cirrhosis of the liver: evaluation of intrarenal blood flow by para-aminohippurate extraction and response to angiotensin. Am J Med. 43:1967;887-896.
11. Kew M.C., Brunt P.W., Varma R.R. Renal and intrarenal blood flow in cirrhosis of the liver. Lancet. 2:1971;504-510.
12. Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal hemodynamics and liver function. Scand J Clin Lab Invest. 37:1977;635-642.
13. Platt J.F., Marn C.S., Baliga P.K., Ellis J.H., Rubin J.M., Merion R.M. Renal dysfunction in hepatic disease: early identification with renal duplex doppler US in patients who undergo liver transplantation. Radiology. 183:1992;801-806.
14. Dagher L., Moore K. The hepatorenal syndrome. Gut. 49:2001;729-737.
15. Arroyo V., Guevara M., Ginès P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology. 122:2002;1658-1676.
16. Schrier R.W., Arroyo V., Bernardi M., Epstein M., Henriksen J.H., Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 8:1988;1151-1157.
17. Schrier R.W., Niederbeger M., Weigert A., Ginès P. Peripheral arterial vasodilation: determinant of functional spectrum of cirrhosis. Semin Liver Dis. 14:1994;14-22.
18. Martin P.Y., Ginès P., Schrier R.W. Role of nitric oxide as mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med. 339:1998;533-541.
19. Wiest R., Groszmann R.J. Nitric oxide an portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis. 19:1999;411-426.
20. Fernández-Seara J., Prieto J., Quiroga J., et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology. 97:1989;1304-1312.
21. Maroto A., Ginès P., Arroyo V., et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology. 17:1993;788-793.
22. Guevara M., Bru C., Ginès P., et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology. 28:1998;39-44.
23. Sugano S., Yamamoto K., Atobe T., et al. Postprandial middle cerebral arterial vasoconstriction in cirrhotic patients: a placebo, controlled evaluation. J Hepatol. 34:2001;373-377.
24. Epstein M. Hepatorenal syndrome. Epstein M. The kidney in liver disease. 4th edn:1996;75-108 Hanley & Belfus, Philadelphia.
25. Papper S., Belsky J.L., Bleifer K.H. Renal failure in Laennec's cirrhosis of the liver: description of clinical and laboratory features. Ann Intern Med. 51:1959;759-773.
26. Shear L., Kleinerman J., Gabuzda G.J. Renal failure in patients with cirrhosis of the liver: I clinical and pathologic characteristics. Am J Med. 39:1965;184-192.
27. Ginès A., Escorsell A., Ginès P., et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology. 105:1993;229-236.
28. Rodés J., Bosch J., Arroyo V. Clinical types and drug therapy of renal impairment in cirrhosis. Postgrad Med J. 51:1975;492-497.
29. Vesin P. Late functional renal failure in cirrhosis with ascites: pathophysiology, diagnosis and treatment. Martinin G.A., Sherlock S. Aktuelle Probleme der Hepatologie. 1962;98-109 Georg Thieme Verlag, Stuttgart.
30. Ginès P., Berl T., Bernardi M., et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 28:1998;851-864.
31. Maroto A., Ginès P., Saló J., et al. Diagnosis of functional renal failure of cirrhosis by Doppler sonography: prognostic value of resistive index. Hepatology. 20:1994;839-844.
32. Guevara M., Ginès P., Fernández-Esparrach G., et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology. 27:1998;35-41.
33. Tristani F.E., Cohn J.H. Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J Clin Invest. 46:1967;1894-1906.
34. Moreau R., Durand F., Poynard T., et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 122:2002;923-930.
35. Ortega R., Ginès P., Uriz J., et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 36:2002;941-948.
36. Bataller R., Ginès P., Guevara M., Arroyo V. Hepatorenal syndrome. Semin Liver Dis. 17:1997;233-248.
37. Follo A., Llovet J.M., Navasa M., et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 20:1994;1495-1501.
38. Sort P., Navasa M., Arroyo V., et al. Effect of plasma volume expansion on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 341:1999;403-409.
39. Rimola A., Garcia-Tsao G., Navasa M., et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol. 32:2000;142-153.
40. Ginès P., Titó Ll, Arroyo V., et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 94:1988;1493-1502.
41. Ginès P., Arroyo V., Rodés J. Ascites, hepatorenal syndrome, and spontaneous bacterial peritonitis. McDonald J., Burroughs A.K., Feagan B. Evidence based gastroenterology and hepatology. 1999;427-442 BMJ Books, London.
42. Del Olmo J.A., Peña A., Serra M.A., Wassel A.H., Benages A., Rodrigo J.M. Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. J Hepatol. 32:2000;19-24.
43. Cárdenas A., Ginès P., Uriz J., et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors and short-term prognosis. Hepatology. 34:2001;671-676.
44. Papadakis M.A., Arieff A.I. Unpredictability of clinical evaluation of renal function in cirrhosis: a prospective study. Am J Med. 82:1987;845-852.
45. Caregaro L., Menon F., Angeli P., et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med. 154:1994;201-205.
46. Navasa M., Rimola A., Rodés J. Bacterial infections in liver disease. Semin Liver Dis. 17:1997;323-333.
47. Boyer T.D., Zia P.K., Reynolds T.B. Effect of indomethacin and prostaglandin A1 in renal function and plasma renin activity in alcoholic liver disease. Gastroenterology. 77:1979;215-222.
48. Henriksen J.H., Ring-Larse H. Renal effects of drugs used in the treatment of portal hypertension. Hepatology. 18:1993;688-695.
49. Salerno F., Badalamenti S. Drug-induced renal failure in cirrhosis. Arroyo V., Ginès P., Rodés J., Schrier R.W. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment. 1999;511-521 Blackwell Science, Malden.
50. Barrett B.J., Parfrey P.S. Prevention of nephrotoxicity induced by radicontrast agents. N Engl J Med. 331:1994;1449-1450.
51. Ginès P., Schrier R.W. Hepatorenal syndrome and renal dysfunction associated with liver disease, Schrier. Gottschalk R.W., Boston: C.W. 6th edn:1997;2099-2128 Little Brown and Co, Schrier RW, Gottschalk CW, Boston.
52. Lhotta K. Beyond hepatorenal syndrome: glomerulonephritis in patients with liver disease. Semin Nephrol. 22:2002;302-308.
53. Dudley F.J., Kanel G.C., Wood J.L., Reynolds T.B. Hepatorenal syndrome without sodium retention. Hepatology. 6:1986;248-259.
54. Carvounis C.P., Nisar S., Guro-Razuman S. Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int. 62:2002;2223-2229.
55. Gonwa T.A., Wilkinson A.H. Liver transplantation and renal function: results in patients with and without hepatorenal syndrome. Epstein M. The kidney in liver disease. 4th edn:1996;529-542 Hanley & Belfus, Philadelphia.
56. Rimola A., Navasa M., Grande L. Liver transplantation in cirrhotic patients with ascites. Arroyo V., Ginès P., Rodés J., Schrier R.W. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment. 1999;522-537 Blackwell Science, Malden.
57. Arroyo V., Bataller R., Guevara M. Treatment of hepatorenal syndrome in cirrhosis. Arroyo V., Ginès P., Rodés J., Schrier R.W. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment. 1999;492-510 Blackwell Science, Malden.
58. Pham P.T., Pham P.C., Wilkinson A.H. The kidney in liver transplantation. Clin Liver Dis. 4:2000;567-590.
59. Wiesner R.H. Who and when to list patients for liver transplantation. Arroyo V., Bosch J., Brugruera M., Rodés J., Sanchez-Tapias J.M. Treatment of liver diseases. 1999;159-176 Masson, Barcelona.
60. Malinchoc M., Kamath P.S., Gordon F.D., Peine C.J., Rank J., Ter Borg PCJ. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 31:2000;864-871.
61. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 33:2001;464-470.
62. Wiesner R.H., McDiarmid S.V., Kamath P.S., et al. MELD and PELD: Application of survival models to liver allocation. Liver Transpl. 7:2001;567-580.
63. Wiesner R.H., Edwards E., Freeman R., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 124:2003;91-96.
64. Rimola A., Gavaler J.S., Schade R.R., el-Lankany S., Starzl T.E., Van Thiel D.H. Effects of renal impairment on liver transplantation. Gastroenterology. 93:1987;148-156.
65. Gonwa A.T., Klintmalm G.B., Levy M., Jennings L.S., Goldstein R.M., Husberg B.S. Impact of pretransplant renal function on survival after liver transplantation. Transplantion. 59:1995;361-365.
66. Nair S., Verma S., Thuluvath P.J. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology. 35:2002;1179-1185.
67. Restuccia T, Guevara M, Ginès P, et al. Impact of pretransplant treatment of hepatorenal syndrome with vasopressin analogues on outcome after liver transplantation: a case-control study. J Hepatol 2003; 38: 69A (abstr).
68. Jeyarajah D.R., Gonwa T.A., McBride M., et al. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. Transplantation. 64:1997;1760-1765.
69. Pomfret E.A., Pomposelli J.J., Jenkins R.L. Live donor liver transplantation. J Hepatol. 34:2001;613-624.
70. Kam I. Adult-adult right hepatic lobe living donor liver transplantation for status 2a patients: too little, too late. Liver Transpl. 8:2002;347-349.
71. Ginès P., Guevara M. Good news for hepatorenal syndrome. Hepatology. 36:2002;504-506.
72. Gülberg V., Bilzer M., Gerbes A.L. Long-term therapy and retreatment of hepatorenal syndrome type I with ornipressin and dopamine. Hepatology. 30:1999;870-875.
73. Hadengue A., Gadano A., Moreau R., et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol. 29:1998;565-570.
74. Uriz J., Ginès P., Cárdenas A., et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 33:2000;43-48.
75. Mulkay J.P., Louis H., Donckier V., et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg. 64:2001;15-19.
76. Halimi C., Bonnard P., Bernard B., et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol. 14:2002;153-158.
77. Angeli P., Volpin R., Gerunda G., et al. Reversal of type 1 HRS with the administration of midodrine and octreotide. Hepatology. 29:1999;1690-1697.
78. Duvoux C., Zanditenas D., Hezode C., et al. Effects of noradrenalin and albumin in patients with type I hepatorrenal syndrome: a pilot study. Hepatology. 36:2002;374-380.
79. Pomier-Layrargues G., Paquin S.C., Hassoun Z., Lafortune M., Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology. 38:2003;238-243.
80. Guevara M., Ginès P., Bandi J.C., et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology. 27:1998;35-41.
81. Brensing K.A., Textor J., Perz J., et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant patients with hepatorenal syndrome: a phase II study. Gut. 47:2000;288-295.
82. Rossle M., Siegerstetter V., Huber M., Ochs A. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. Liver. 18:1998;73-89.
83. Bosch J. Salvage transjugular intrahepatic portosystemic shunt: is it really life-saving? J Hepatol. 35:2001;658-660.
84. Perez G.O., Golper T.A., Epstein M., Oster J.R. Dyalisis hemofiltration, and other extracorporeal techniques in the treatment of renal complications of liver disease. Epstein M. The kidney in liver disease. 4th edn:1996;517-528 Hanley & Belfus, Philadelphia.
85. Mitzner S.R., Stange J., Klammt S., et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 6:2000;277-286.
86. Holt S., Goodier D., Marley R., et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet. 353:1999;294-295.
87. Ginès P., Uriz J., Calahorra B., et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroeterology. 123:2002;1839-1847.
88. Alessandria C., Debernardi W., Marzano A., Barletti C., Fadda M., Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol. 14:2002;1363-1368.
89. Ochs A., Rössle M., Haag K., et al. The transjugular intrahepatic portosystemic stent shunt procedure for refractory ascites. N Engl J Med. 332:1995;1192-1197.
90. Michl P., Gulberg V., Bilzer M., Waggershauser T., Reiser M., Gerbes A.L. Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: effects in patients with organic or functional renal failure. Scand J Gastroenterol. 35:2000;654-658.
91. Rossle M., Ochs A., Gulberg V., et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med. 342:2000;1701-1707.
92. Sanyal A.J., Genning C., Reddy R.K., et al. The North American Study of Treatment for Refractory Ascites (NASTRA). Gastroenterology. 124:2003;634-641.
93. Amirkhosravi A., Meyer T., Warnes G., et al. Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor. Thromb Haemost. 80:1998;598-602.